Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Mexico City Mexico

Organization Overview

First Clinical Trial
2006
NCT02525159
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Instituto Nacional de Perinatología Isidro Espinosa de los Reyes | Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes | Instituto Nacional de Perinatología Isidro Espinosa de los Reyes

Active Ingredients

Drugs in Phase 4 Trials (1)

sitagliptin (januvia) (1 trial)

Drugs in Phase 3 Trials (2)

bovine colostrum (1 trial)

diindolylmethane (1 trial)

Drugs in Other Trials (4)

cocoa flavanols (1 trial)

resveratrol (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Diabetes, Gestational (Phase 4)

Immune System Diseases (Phase 3)

Infant, Premature, Diseases (Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Premature Birth (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7